BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Shanghai Junshi Bioscience readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Shanghai Junshi Bioscience's drug
 s run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06885385-2239@assetmemo.bio
DTSTAMP:20261121T005436Z
DTSTART;VALUE=DATE:20261127
DTEND;VALUE=DATE:20261128
SUMMARY:JS207: Phase 2 readout est. (NCT06885385)
DESCRIPTION:JS207\, phase 2.\nStudy: A Phase 2 Study Evaluating the Safety 
 and Efficacy of JS207 With or Without JS015 in Combination With Chemothera
 py in Patients With Colorectal Cancer\nEstimated primary completion: 27 No
 vember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/js207#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT068853
 85
URL:https://assetmemo.bio/drug/js207#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03859128-2018@assetmemo.bio
DTSTAMP:20261121T005436Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Toripalimab: Phase 2/3 readout est. (NCT03859128)
DESCRIPTION:Toripalimab\, phase 2/3.\nStudy: Toripalimab or Placebo as Adju
 vant Therapy in Hepatocellular Carcinoma After Radical Resection\nEstimate
 d primary completion: 31 December 2026. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/toripalimab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT03859128
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04523493-2018@assetmemo.bio
DTSTAMP:20261121T005436Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Toripalimab: Phase 3 readout est. (NCT04523493)
DESCRIPTION:Toripalimab\, phase 3.\nStudy: Phase III Study of Toripalimab
 （JS001） Combined With Lenvatinib for Advanced HCC\nEstimated primary c
 ompletion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/toripalimab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT04523493
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06208410-9068@assetmemo.bio
DTSTAMP:20261121T005436Z
DTSTART;VALUE=DATE:20270226
DTEND;VALUE=DATE:20270227
SUMMARY:JS105: Phase 1/2 readout est. (NCT06208410)
DESCRIPTION:JS105\, phase 1/2.\nStudy: A Clinical Study of JS105 in Combina
 tion With Other Anti-tumor Therapies in Patients With Solid Tumors\nEstima
 ted primary completion: 26 February 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/js105#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT06208410
URL:https://assetmemo.bio/drug/js105#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05180734-2018@assetmemo.bio
DTSTAMP:20261121T005436Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Toripalimab: Phase 3 readout est. (NCT05180734)
DESCRIPTION:Toripalimab\, phase 3.\nStudy: PD1 Combined With Chemotherapy f
 or Adjuvant Treatment of Gastric Cancer\nEstimated primary completion: 31 
 March 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/toripalim
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 5180734
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06944470-2239@assetmemo.bio
DTSTAMP:20261121T005436Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:JS207: Phase 2 readout est. (NCT06944470)
DESCRIPTION:JS207\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: JS207 Com
 bined With Chemotherapy in Subjects With Stage II-III NSCLC\nEstimated pri
 mary completion: 30 April 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/js207#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT06944470
URL:https://assetmemo.bio/drug/js207#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04848753-2018@assetmemo.bio
DTSTAMP:20261121T005436Z
DTSTART;VALUE=DATE:20270512
DTEND;VALUE=DATE:20270513
SUMMARY:Toripalimab: Phase 3 readout est. (NCT04848753)
DESCRIPTION:Toripalimab\, phase 3.\nStudy: Perioperative Toripalimab (JS001
 ) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Local
 ly Advanced Thoracic Esophageal Squamous Cell Carcinoma\nEstimated primary
  completion: 12 May 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/toripalimab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT04848753
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05342194-2018@assetmemo.bio
DTSTAMP:20261121T005436Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Toripalimab: Phase 3 readout est. (NCT05342194)
DESCRIPTION:Toripalimab\, phase 3\, Cholangiocarcinoma.\nStudy: Toripalimab
  Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Adv
 anced ICC: a Phase III Study\nEstimated primary completion: 31 May 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/toripalimab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT05342194
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07484724-2018@assetmemo.bio
DTSTAMP:20261121T005436Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Toripalimab: Phase 2 readout est. (NCT07484724)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: A Study Evaluating the Safety an
 d Efficacy of JS212 Combination Therapy in Patients With Advanced Esophage
 al Squamous Cell Carcinoma\nEstimated primary completion: 30 June 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/toripalimab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07484724
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06095583-2018@assetmemo.bio
DTSTAMP:20261121T005436Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Toripalimab: Phase 3 readout est. (NCT06095583)
DESCRIPTION:Toripalimab\, phase 3.\nStudy: Phase 3 Study of Toripalimab Alo
 ne or in Combination With Tifcemalimab as Consolidation Therapy in Patient
 s With Limited-stage Small Cell Lung Cancer (LS-SCLC)\nEstimated primary c
 ompletion: 31 July 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/toripalimab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06095583
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07309276-2018@assetmemo.bio
DTSTAMP:20261121T005436Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Toripalimab: Phase 2 readout est. (NCT07309276)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: A Phase II Clinical Study Evalua
 ting the Combination Therapy of JS212 in Patients With Advanced Lung Cance
 r\nEstimated primary completion: 30 November 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/toripalimab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07309276
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07480733-2018@assetmemo.bio
DTSTAMP:20261121T005436Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Toripalimab: Phase 2 readout est. (NCT07480733)
DESCRIPTION:Toripalimab\, phase 2.\nStudy: Phase II Study of JS212/JS213 as
  Monotherapy and in Combination in Patients With Advanced Malignant Solid 
 Tumors\nEstimated primary completion: 30 November 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/toripalimab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07480733
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07503756-2239@assetmemo.bio
DTSTAMP:20261121T005436Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:JS207: Phase 2 readout est. (NCT07503756)
DESCRIPTION:JS207\, phase 2.\nStudy: JS212 Combination Therapies in Metasta
 tic Colorectal Cancer\nEstimated primary completion: 30 December 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/js207#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07503756
URL:https://assetmemo.bio/drug/js207#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06888830-2571@assetmemo.bio
DTSTAMP:20261121T005436Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:JS212: Phase 1/2 readout est. (NCT06888830)
DESCRIPTION:JS212\, phase 1/2.\nStudy: A Phase I/II Clinical Study to Evalu
 ate the Safety\, Tolerability\, Pharmacokinetics and Initial Efficacy of J
 S212 in Subjects With Advanced Malignant Solid Tumour\nEstimated primary c
 ompletion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/js212#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06888830
URL:https://assetmemo.bio/drug/js212#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06969027-2239@assetmemo.bio
DTSTAMP:20261121T005436Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:JS207: Phase 2 readout est. (NCT06969027)
DESCRIPTION:JS207\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: JS207Comb
 ined With Chemotherapy in First-line Treatment of Advanced NSCLC\nEstimate
 d primary completion: 31 December 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/js207#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT06969027
URL:https://assetmemo.bio/drug/js207#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07876557-2018@assetmemo.bio
DTSTAMP:20261121T005436Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Toripalimab: Phase 2 readout est. (NCT07876557)
DESCRIPTION:Toripalimab\, phase 2\, Breast Cancer.\nStudy: A Clinical Study
  to Evaluate the Efficacy and Safety of JS212 Monotherapy or Combination T
 herapy in Recurrent or Metastatic Triple-negative Breast Cancer(TNBC)\nEst
 imated primary completion: 31 December 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/toripalimab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07876557
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06954467-2239@assetmemo.bio
DTSTAMP:20261121T005436Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:JS207: Phase 2 readout est. (NCT06954467)
DESCRIPTION:JS207\, phase 2\, Hepatocellular Carcinoma.\nStudy: JS207 Combi
 ned With JS007 as First-line Treatment for Advanced Hepatocellular Carcino
 ma\nEstimated primary completion: 31 December 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/js207#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06954467
URL:https://assetmemo.bio/drug/js207#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07045311-2239@assetmemo.bio
DTSTAMP:20261121T005436Z
DTSTART;VALUE=DATE:20280322
DTEND;VALUE=DATE:20280323
SUMMARY:JS207: Phase 2 readout est. (NCT07045311)
DESCRIPTION:JS207\, phase 2\, Breast Cancer.\nStudy: JS207 Combination Ther
 apy in Triple-negative Breast Cancer\nEstimated primary completion: 22 Mar
 ch 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/js207#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07045311
URL:https://assetmemo.bio/drug/js207#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07518160-2047@assetmemo.bio
DTSTAMP:20261121T005436Z
DTSTART;VALUE=DATE:20280423
DTEND;VALUE=DATE:20280424
SUMMARY:JS111: Phase 2 readout est. (NCT07518160)
DESCRIPTION:JS111\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: JS212 Plu
 s JS111 in EGFR-Mutant Advanced NSCLC: A Phase II Study\nEstimated primary
  completion: 23 April 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/js111#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07518160
URL:https://assetmemo.bio/drug/js111#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06940401-2047@assetmemo.bio
DTSTAMP:20261121T005436Z
DTSTART;VALUE=DATE:20280730
DTEND;VALUE=DATE:20280731
SUMMARY:JS111: Phase 1/2 readout est. (NCT06940401)
DESCRIPTION:JS111\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: JS111 i
 n Patients With Advanced NSCLC Harboring EGFR Mutations\nEstimated primary
  completion: 30 July 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/js111#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT06940401
URL:https://assetmemo.bio/drug/js111#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07207070-9068@assetmemo.bio
DTSTAMP:20261121T005436Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:JS105: Phase 3 readout est. (NCT07207070)
DESCRIPTION:JS105\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nStudy: A
  Randomised\, Open-label\, Multicentre Phase III Clinical Study to Evaluat
 e the Efficacy and Safety of JS105 Combined With Dalpiciclib and Fulvestra
 nt Compared With Dalpiciclib and Fulvestrant in Patients With PIK3CA-mutat
 ed\, HR-positive\, HER2-negative Recurrent or Metastatic Breast Cancer.\nE
 stimated primary completion: 31 May 2029. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/js105#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07207070
URL:https://assetmemo.bio/drug/js105#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07823348-2239@assetmemo.bio
DTSTAMP:20261121T005436Z
DTSTART;VALUE=DATE:20291030
DTEND;VALUE=DATE:20291031
SUMMARY:JS207: Phase 3 readout est. (NCT07823348)
DESCRIPTION:JS207\, phase 3\, Hepatocellular Carcinoma.\nStudy: JS207 Plus 
 JS007 Versus Toripalimab Plus Bevacizumab as First-Line Treatment for Adva
 nced Liver Cancer\nEstimated primary completion: 30 October 2029. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/js207#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07823348
URL:https://assetmemo.bio/drug/js207#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
